Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Condition(s) studied

Investigational drug(s) / intervention(s)

Adaptive radiotherapy: Volumetric and biological adaptive radiotherapy will be delivered based on interval imaging with MRI and PET scan during treatment.

Study summary

Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.

Modifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.

The aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.

Eligibility

Primary outcome measure(s)

• Proportion of patients undergoing volumetric and biological adaptation. Cumulative rate of symptomatic radionecrosis (RN) at 2 years. — 2 years
  Proportion of patients where modification of radiation plan was done.
• Cumulative rate of symptomatic radionecrosis at 2 years — 4 years
  Patients developing symptomatic radionecerosis will be analyzed using Kaplan-Meier survival method.

Trial sites (1)

More Tata Memorial Centre trials in India

Other trials for the same condition